Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Rating of “Moderate Buy” by Brokerages

Cogent Biosciences, Inc. (NASDAQ:COGT) has been given an average recommendation of “Moderate Buy” by the fourteen research firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, nine have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $43.7273.

Several research analysts have weighed in on COGT shares. Piper Sandler increased their price target on shares of Cogent Biosciences from $39.00 to $52.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Robert W. Baird set a $35.00 price target on shares of Cogent Biosciences in a report on Thursday, February 19th. Wall Street Zen cut shares of Cogent Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, January 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Cogent Biosciences in a report on Friday, April 10th. Finally, Wedbush reissued an “outperform” rating and issued a $55.00 price target on shares of Cogent Biosciences in a report on Tuesday, March 17th.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. CWM LLC raised its holdings in Cogent Biosciences by 4.9% in the 4th quarter. CWM LLC now owns 5,858 shares of the technology company’s stock valued at $208,000 after acquiring an additional 276 shares during the period. Steward Partners Investment Advisory LLC grew its position in shares of Cogent Biosciences by 16.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,159 shares of the technology company’s stock worth $77,000 after purchasing an additional 300 shares in the last quarter. Optimize Financial Inc grew its position in shares of Cogent Biosciences by 1.4% during the 4th quarter. Optimize Financial Inc now owns 33,024 shares of the technology company’s stock worth $1,173,000 after purchasing an additional 472 shares in the last quarter. Nisa Investment Advisors LLC grew its position in shares of Cogent Biosciences by 35.7% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,855 shares of the technology company’s stock worth $66,000 after purchasing an additional 488 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its position in shares of Cogent Biosciences by 2.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 25,014 shares of the technology company’s stock worth $888,000 after purchasing an additional 527 shares in the last quarter.

Cogent Biosciences Price Performance

Shares of COGT stock opened at $34.74 on Monday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 15.14 and a current ratio of 15.14. The firm’s 50-day moving average is $36.35 and its 200-day moving average is $34.81. The stock has a market cap of $5.94 billion, a price-to-earnings ratio of -16.01 and a beta of 0.37. Cogent Biosciences has a 52-week low of $4.55 and a 52-week high of $43.73.

Cogent Biosciences (NASDAQ:COGT) last released its quarterly earnings results on Tuesday, May 5th. The technology company reported ($0.53) earnings per share for the quarter, meeting the consensus estimate of ($0.53). Sell-side analysts predict that Cogent Biosciences will post -2.18 EPS for the current year.

About Cogent Biosciences

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.